
News|Articles|October 30, 2025
- Vol.27/No.1
- Volume 27
- Issue 1
Tackling Drug Shortages in Hematologic Oncology Care Requires Nuance and Adaptability
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Harry P. Erba, MD, PhD; and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.
Advertisement
Advertisement
Drug shortages have touched nearly every area of cancer care throughout the years, but their effects can be particularly felt in hematologic oncology, where certain agents are often needed as backbones of treatment and lymphodepleting regimens. In order to best prepare for these inevitable shortages and to minimize their effect on patient care, oncologists must have suitable alternatives in mind that will not compromise the efficacy and safety of a therapeutic regimen.
Related to this article

An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.

Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.

A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement

